Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Net Income towards Common Stockholders fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year increase of 1491.11%. This contributed to the annual value of -$34.1 million for FY2024, which is 1916.98% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Net Income towards Common Stockholders is -$12.1 million, which was down 1659.63% from -$10.1 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Net Income towards Common Stockholders ranged from a high of $1.4 million in Q1 2021 and a low of -$22.9 million during Q4 2023
  • Over the past 5 years, SAB Biotherapeutics' median Net Income towards Common Stockholders value was -$7.1 million (recorded in 2022), while the average stood at -$7.3 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Net Income towards Common Stockholders tumbled by 84592.72% in 2023 and then skyrocketed by 5014.74% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Net Income towards Common Stockholders (Quarter) stood at -$11.6 million in 2021, then soared by 31.83% to -$7.9 million in 2022, then tumbled by 190.26% to -$22.9 million in 2023, then skyrocketed by 50.15% to -$11.4 million in 2024, then fell by 5.9% to -$12.1 million in 2025.
  • Its last three reported values are -$12.1 million in Q3 2025, -$10.1 million for Q2 2025, and -$5.2 million during Q1 2025.